Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 5, 2025Clinical pharmacology and therapyOpen Access

Incretin-based pharmacotherapy: from physiological mechanisms to management of type 2 diabetes and obesity

View Full Paper
Ask AI
Bookmark
Share

Authors

EKE.V. KhaikinaСКС. Н. КозловAZA.I. Zaleskaya

Discussion

Loading...

Member takes

Overview

Review highlights incretin impacts on glucose metabolism and obesity treatment, indicating its growing role.

Key Points

  • Incretin-based pharmacotherapy shows significant efficacy in managing type 2 diabetes and obesity, promoting better health outcomes.
  • Dipeptidyl peptidase-4 inhibitors and GLP-1 receptor agonists are key components of this therapy, enhancing metabolic regulation.
  • This pharmacotherapy reduces the risk of metabolically associated diseases, providing vital health benefits.
  • The advantages of incretin drugs include high efficacy and favorable tolerability, making them ideal for patient management.

Cite This Study

Khaikina et al. (2025) studied this question.

synapsesocial.com/papers/68e24e60d6d66a53c2473499https://doi.org/10.32756/0869-5490-2025-3-40-46
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Incretin Signaling Neighborhoods and Adverse Drug Reactions2025
  2. 2Incretins for obesity: closer to a nicotine patch than a silver bullet2025
  3. 3Efficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare2025 · 7 citations
  4. 4Novel GLP-1-Based Medications for Type 2 Diabetes and Obesity2025
  5. 5The role of gip in carbohydrate metabolism: Implications in the development of therapies for T2DM, a narrative review.2025